Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Compare

2,313 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AXSM Analyst Ratings

Strong Buy

14 Buy

1 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Axsome

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AXSM Stock 12 Month Forecast

Average Price Target

$209.54

▲(13.73% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $209.54 with a high forecast of $260.00 and a low forecast of $153.00. The average price target represents a 13.73% change from the last price of $184.25.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"83":"$83","172":"$172","261":"$261","127.5":"$127.5","216.5":"$216.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":260,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$260.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":209.54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$209.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":153,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$153.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[83,127.5,172,216.5,261],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,182.64,188.5907692307692,194.54153846153844,200.4923076923077,206.44307692307692,212.39384615384614,218.34461538461537,224.2953846153846,230.24615384615385,236.19692307692307,242.1476923076923,248.09846153846155,254.04923076923075,{"y":260,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,182.64,184.70923076923074,186.77846153846153,188.84769230769228,190.91692307692307,192.98615384615383,195.0553846153846,197.12461538461537,199.19384615384615,201.2630769230769,203.3323076923077,205.40153846153845,207.47076923076924,{"y":209.54,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,182.64,180.35999999999999,178.07999999999998,175.79999999999998,173.51999999999998,171.23999999999998,168.95999999999998,166.68,164.4,162.12,159.84,157.56,155.28,{"y":153,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":84.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 75,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.54,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 81,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 77,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.97,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.57,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.99,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$260.00

Average Price Target$209.54

Lowest Price Target$153.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Leonid Timashev

RBC Capital

$219

Buy

18.86%

Upside

Reiterated

02/02/26

RBC Capital Remains a Buy on Axsome Therapeutics (AXSM)

Joseph Thome

TD Cowen

$190→$195

Buy

5.83%

Upside

Reiterated

01/29/26

TD Cowen Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

Graig Suvannavejh

Mizuho Securities

$217

Buy

17.77%

Upside

Reiterated

01/22/26

Analysts Conflicted on These Healthcare Names: Hinge Health, Inc. Class A (NYSE: HNGE), Axsome Therapeutics (NASDAQ: AXSM) and TG Therapeutics (NASDAQ: TGTX)

Ram Selvaraju

H.C. Wainwright

$200→$260

Buy

41.11%

Upside

Reiterated

01/20/26

Reaffirming Axsome Therapeutics as a Buy on Robust Commercial Growth and Advancing Late‑Stage Pipeline, With a Raised $260 Price Target

David Amsellem

Piper Sandler

$148→$223

Buy

21.03%

Upside

Reiterated

01/16/26

Axsome Therapeutics price target raised to $223 from $148 at Piper SandlerAxsome Therapeutics price target raised to $223 from $148 at Piper Sandler

Pete Stavropoulos

Cantor Fitzgerald

$153

Buy

-16.96%

Downside

Reiterated

01/14/26

Cantor Fitzgerald Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)

Benjamin Burnett

Wells Fargo

$157→$193

Buy

4.75%

Upside

Reiterated

01/13/26

Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Adaptive Biotechnologies (ADPT)

Brian Skorney

Robert W. Baird

$157→$209

Buy

13.43%

Upside

Reiterated

01/13/26

Axsome Therapeutics price target raised to $209 from $157 at BairdAxsome Therapeutics price target raised to $209 from $157 at Baird

Ami Fadia

Needham

$225

Buy

22.12%

Upside

Reiterated

01/12/26

Buy Rating on Axsome Therapeutics Backed by Strong Auvelity and Sunosi Outperformance Despite Slower Symbravo Ramp

Myles Minter

William Blair

Buy

―

Reiterated

01/12/26

Axsome Therapeutics: Strong Commercial Execution and De-Risked Pipeline Support Buy Rating and Long-Term Growth

Sean Laaman

Morgan Stanley

$196→$204

Hold

10.72%

Upside

Downgraded

01/08/26

Axsome Therapeutics downgraded to Equal Weight from Overweight at Morgan StanleyAxsome Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley

Ashwani Verma

UBS

$163→$248

Buy

34.60%

Upside

Reiterated

01/06/26

UBS Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)

Joon Lee

Truist Financial

Buy

―

Reiterated

01/02/26

Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Glaukos (GKOS)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$200

Buy

8.55%

Upside

Reiterated

12/17/25

Axsome Therapeutics (AXSM) Gets a Buy from Jefferies

Jason Gerberry

Bank of America Securities

$178

Buy

-3.39%

Downside

Reiterated

12/08/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Leonid Timashev

RBC Capital

$219

Buy

18.86%

Upside

Reiterated

02/02/26

RBC Capital Remains a Buy on Axsome Therapeutics (AXSM)

Joseph Thome

TD Cowen

$190→$195

Buy

5.83%

Upside

Reiterated

01/29/26

TD Cowen Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

Graig Suvannavejh

Mizuho Securities

$217

Buy

17.77%

Upside

Reiterated

01/22/26

Analysts Conflicted on These Healthcare Names: Hinge Health, Inc. Class A (NYSE: HNGE), Axsome Therapeutics (NASDAQ: AXSM) and TG Therapeutics (NASDAQ: TGTX)

Ram Selvaraju

H.C. Wainwright

$200→$260

Buy

41.11%

Upside

Reiterated

01/20/26

Reaffirming Axsome Therapeutics as a Buy on Robust Commercial Growth and Advancing Late‑Stage Pipeline, With a Raised $260 Price Target

David Amsellem

Piper Sandler

$148→$223

Buy

21.03%

Upside

Reiterated

01/16/26

Axsome Therapeutics price target raised to $223 from $148 at Piper SandlerAxsome Therapeutics price target raised to $223 from $148 at Piper Sandler

Pete Stavropoulos

Cantor Fitzgerald

$153

Buy

-16.96%

Downside

Reiterated

01/14/26

Cantor Fitzgerald Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)

Benjamin Burnett

Wells Fargo

$157→$193

Buy

4.75%

Upside

Reiterated

01/13/26

Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Adaptive Biotechnologies (ADPT)

Brian Skorney

Robert W. Baird

$157→$209

Buy

13.43%

Upside

Reiterated

01/13/26

Axsome Therapeutics price target raised to $209 from $157 at BairdAxsome Therapeutics price target raised to $209 from $157 at Baird

Ami Fadia

Needham

$225

Buy

22.12%

Upside

Reiterated

01/12/26

Buy Rating on Axsome Therapeutics Backed by Strong Auvelity and Sunosi Outperformance Despite Slower Symbravo Ramp

Myles Minter

William Blair

Buy

―

Reiterated

01/12/26

Axsome Therapeutics: Strong Commercial Execution and De-Risked Pipeline Support Buy Rating and Long-Term Growth

Sean Laaman

Morgan Stanley

$196→$204

Hold

10.72%

Upside

Downgraded

01/08/26

Axsome Therapeutics downgraded to Equal Weight from Overweight at Morgan StanleyAxsome Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley

Ashwani Verma

UBS

$163→$248

Buy

34.60%

Upside

Reiterated

01/06/26

UBS Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)

Joon Lee

Truist Financial

Buy

―

Reiterated

01/02/26

Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Glaukos (GKOS)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$200

Buy

8.55%

Upside

Reiterated

12/17/25

Axsome Therapeutics (AXSM) Gets a Buy from Jefferies

Jason Gerberry

Bank of America Securities

$178

Buy

-3.39%

Downside

Reiterated

12/08/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Axsome Therapeutics

3 Months

xxx

Success Rate

10/14 ratings generated profit

Average Return

+10.96%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +10.96% per trade.

1 Year

Ram SelvarajuH.C. Wainwright

Success Rate

14/14 ratings generated profit

Average Return

+53.09%

reiterated a buy rating 15 days ago

Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +53.09% per trade.

2 Years

xxx

Success Rate

32/32 ratings generated profit

Average Return

+90.12%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +90.12% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AXSM Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AXSM has received 43 Buy Ratings, 22 Hold Ratings, and 0 Sell Ratings. AXSM average Analyst price target in the past 3 months is 209.54.

Each month's total comprises the sum of three months' worth of ratings.

AXSM Financial Forecast

AXSM Earnings Forecast

Next quarter’s earnings estimate for AXSM is -$0.67 with a range of -$1.16 to -$0.28. The previous quarter’s EPS was -$0.94. AXSM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year AXSM has Performed in-line its overall industry.

AXSM Sales Forecast

Next quarter’s sales forecast for AXSM is $192.92M with a range of $180.70M to $199.38M. The previous quarter’s sales results were $170.99M. AXSM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.12% of the time in the same period. In the last calendar year AXSM has Performed in-line its overall industry.

AXSM Stock Forecast FAQ

What is AXSM’s average 12-month price target, according to analysts?

Based on analyst ratings, Axsome Therapeutics Inc’s 12-month average price target is 209.54.

What is AXSM’s upside potential, based on the analysts’ average price target?

Axsome Therapeutics Inc has 13.73% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AXSM a Buy, Sell or Hold?

Axsome Therapeutics Inc has a consensus rating of Strong Buy which is based on 14 buy ratings, 1 hold ratings and 0 sell ratings.

What is Axsome Therapeutics Inc’s price target?

The average price target for Axsome Therapeutics Inc is 209.54. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $260.00 ,the lowest forecast is $153.00. The average price target represents 13.73% Increase from the current price of $184.25.

What do analysts say about Axsome Therapeutics Inc?

Axsome Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of AXSM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

AXSM Analyst Ratings

AXSM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Axsome Therapeutics

AXSM Analyst Recommendation Trends

AXSM Financial Forecast

AXSM Earnings Forecast

AXSM Sales Forecast

AXSM Stock Forecast FAQ

Detailed List of Analyst Forecasts